Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 118 publications.
Fortuny J, Gilsenan AW, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cohort study of the relative incidence of major cardiovascular events among patients initiating prucalopride versus a matched comparator cohort in a multinational study: study design and comparability of cohorts. Poster presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):627.
Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero OF, Flynn RW, Garcia-Rodriguez L, Harding A, Kollhorst B, Karlsson P, Linner L, MacDonald TM, Odsbu I, Plana E, Ruigomez A, Schink T, Ziemiecki R, Andrews EB. Cardiovascular safety of prucalopride for chronic constipation: a multinational population-based cohort study. Presented at the 35th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2019. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2019 Aug 20; 28(S2):33. doi: 10.1002/pds.4864.
Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus lenalidomide plus dexamethasone versus lenalidomide plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Pollux trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 11, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):4711. doi: 10.1182/blood.V130.Suppl_1.4711.4711.
Maiese EM, Graham CN, Hawe E, Le Moine JG, Abraham I, Senbetta M. Cost-effectiveness of daratumumab plus bortezomib and dexamethasone versus bortezomib plus dexamethasone for treatment of patients with multiple myeloma who have received at least one prior therapy: an analysis of the Castor Trial. Poster presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition; December 10, 2017. Atlanta, GA. [abstract] Blood. 2017 Dec 7; 130(Supplement 1):3400. doi: 10.1182/blood.V130.Suppl_1.3400.3400.
Cainzos-Achirica M, Varas-Lorenzo C, Pottegard A, Asmar J, Plana E, Rasmussen L, Bizouard G, Forns J, Hellfritzsch M, Zint K, Perez-Gutthann S, Pladevall-Vila M. Evaluation of potential off-label prescribing of dabigatran etexilate in France, Denmark, and the United Kingdom and associated methodological challenges. Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):566. doi: 10.1002/pds.
Margulis AV, Varas-Lorenzo C, Bui CL, Mcquay LJ, Ziemiecki R, Reynolds M, Rebordosa C, Pladevall-Vila M, Fortuny J, Rivero-Ferrer E, Plana E, Atsma WJ, Appenteng K, Franks B, de Vogel S, D'Silva M, Perez-Gutthann S, Arana A. Validation of cardiovascular events and covariates in CPRD GOLD using questionnaires to general practitioners (GPS). Presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):255-6.
Puig S, Marcoval J, Paradelo C, Azon A, Bartralot R, Bel S, Bigata X, Boada A, Campoy A, Carrera C, Curco N, Dalmau J, Ferrandiz C, Ferrerres JR, Formigon M, Gallardo F, Gonzalez A, Just M, Llistosella E, Marti RM, Nogues ME, Pedragosa R, Pujol JA, Roldan-Marin R, Sabat M, Salleras M, Smandia JA, Zaballos P, Plana Hortoneda E, Malvehy J. Melanoma incidence increases in the elderly of Catalonia but not in the younger population: effect of prevention or consequence of immigration? Acta Derm Venereol. 2015 Apr 15;95(4):422-6.

Pages